Pipeline, Commercial Needs Drive Active China Licensing Scene In July

July was an active month for deals between Chinese biopharma firms, as some looked to build their pipelines and others for partners to help commercialize products moving to market. Two ADCs, a GLP-1R/GIPR fusion protein and an IL-4Rα antibody were among the assets changing hands.